Dr. Kipps makes complex science accessible as he reviews the new understanding of CLL and how they translate into new therapies and repurposing of old therapies. See bkoffman,blogspot.com for the third part of the ASH 2012 interview.
ASH 2012: Dr Kipps Interview Part 3 on genetic... - CLL Support
ASH 2012: Dr Kipps Interview Part 3 on genetics, epigenetics, and new and old CLL therapies
Written by
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
ASH 2012 Interview: Dr Jeff Sharman "Why New CLL Treatments Supersede FCR"
Dr Sharman's blog http://www.cll-nhl.com, is well worth keeping an eye on for pertinent but easily...
ASH 2016: Dr. Seymour on Combination therapies with venetoclax
Hi,
I am a big believer in combination therapies for CLL.
This week I'm posting an interview on our...
ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance
Venetoclax was changed how we treat CLL, but it doesn't work for everyone and it doesn't always...
OncLive 9 CLL Videos - Optimizing the Treatment of CLL With Novel Therapies and more Take-home messages from ASH 2021
The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for...
ASH 2013: Dr. John Pagel Speculates on the Future of CLL Therapies including the late breaking data on Idelalisib
ASH 2013: Dr. John Pagel Speculates on the Future of CLL (chronic lymphocytic leukemia) Therapies...
Related Posts
Video interviews; CLL 'Hot Topics and Maturing Data' ASH 2019: Prof John Gribben, Prof Pete Hillmen, Dr George Follows & Dr Renata Walewska - CLL Society interview - Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Patients with CLL/SLL January 13, 2023
- Part 2 of ASH Interview with Dr. Sharman, a patient meeting in Seattle and off to iwCLL later tonight
- Dr. O'Brien on how she treats CLL frontline and Dr. Pagel on new ways to block BTK
- ASH 2018: Dr. Lindsey Roeker research from ASH 2018 on real world use of venetoclax for CLL
